New hope for Hard-to-Treat cancers: drug targets MTAP deletion

NCT ID NCT07492680

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 8 times

Summary

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: BMS-986504 (also called MRTX1719 or Navlimetostat)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific genetic deletion (MTAP).
What could go wrong: This is an early phase 2 trial, so the drug may not work or may cause side effects. It is only for people with a specific tumor marker, so it won't apply to most cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

May 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must have histologically confirmed diagnosis of advanced and/or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue. * Depending on the cohort enrolled, participants must have received standard therapies appropriate for their tumor type and stage with disease progression on or after the most recent treatment (there must be no available treatment with curative intent or participant is ineligible or declines treatment) or be treatment-naïve with no prior systemic anticancer therapy for their unresectable or metastatic disease. * Participant must have presence of at least one measurable tumor lesion per RECIST v1.1 or mRECIST at baseline. * Coagulation function: International normalized ratio (INR) and activated partial thromboplastin time (APTT) must be ≤ 1.5 × ULN; subjects with liver metastasis or liver cancer must be ≤ 2 × ULN. * Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: * Participants must not have prior treatment with a PRMT5 or Methionine adenosyl transferase 2A (MAT2A) inhibitor. * Participants must not have active brain metastases or carcinomatous meningitis. Participants are eligible if brain metastases are adequately treated, and participants are neurologically stable for at least 2 weeks prior to enrollment without the use of corticosteroids or are on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent). * Participants must not have history of gastrointestinal disease or other gastrointestinal conditions within 6 months prior to enrollment (including uncontrolled nausea, vomiting, malabsorption syndrome or non-gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess) likely to alter absorption of study treatment or result in inability to swallow oral medications. * Participants must not have inadequate organ function, as determined by laboratory testing within the screening period. * Participants must not have active viral HBV or HCV hepatitis. * Other protocol defined inclusion/exclusion criteria applies.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer melanoma metastatic malignant neoplasm metastatic neoplasm neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

58 sites in 13 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, Seoul-teukbyeolsi [Seoul], 05505, South Korea
Cork University Hospital
RECRUITING

Cork, T12 E8YV, Ireland
Emory University - Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 201321, China
Haukeland Universitetssjukehus
RECRUITING

Bergen, Hordaland, 5021, Norway
Hospital Universitario Virgen Del Rocio
RECRUITING

Seville, 41013, Spain
Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21287, United States
Local Institution - 0007
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 0021
NOT_YET_RECRUITING

Toronto, Ontario, M4N 3M5, Canada
Local Institution - 0033
NOT_YET_RECRUITING

Madrid, 28028, Spain
Local Institution - 0034
NOT_YET_RECRUITING

Milan, 20133, Italy
Local Institution - 0039
NOT_YET_RECRUITING

Heidelberg, 69120, Germany
Local Institution - 0047
NOT_YET_RECRUITING

Würzburg, 97080, Germany
Local Institution - 0049
NOT_YET_RECRUITING

München, 81675, Germany
Local Institution - 0050
NOT_YET_RECRUITING

Naples, 80131, Italy
Local Institution - 0051
NOT_YET_RECRUITING

Vancouver, British Columbia, V2S 0C2, Canada
Local Institution - 0061
NOT_YET_RECRUITING

Leipzig, 04103, Germany
Local Institution - 0063
NOT_YET_RECRUITING

Shatin, NT, Hong Kong
Local Institution - 0068
NOT_YET_RECRUITING

Barcelona, Barcelona [Barcelona], 08035, Spain
Local Institution - 0071
NOT_YET_RECRUITING

Hospitalet, Barcelona [Barcelona], 08907, Spain
Local Institution - 0073
NOT_YET_RECRUITING

Siena, Tuscany, 53100, Italy
Local Institution - 0074
NOT_YET_RECRUITING

Paris, 75010, France
Local Institution - 0075
NOT_YET_RECRUITING

Pierre-Bénite, Rhône, 69310, France
Local Institution - 0078
NOT_YET_RECRUITING

Dijon, Côte-d'Or, 21079, France
Local Institution - 0081
NOT_YET_RECRUITING

Mainz, Rhineland-Palatinate, 55131, Germany
Local Institution - 0082
NOT_YET_RECRUITING

Perugia, 06156, Italy
Local Institution - 0085
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Local Institution - 0086
NOT_YET_RECRUITING

Seattle, Washington, 98109, United States
Local Institution - 0096
NOT_YET_RECRUITING

San Francisco, California, 94158, United States
Local Institution - 0100
NOT_YET_RECRUITING

Durham, North Carolina, 27705, United States
Local Institution - 0114
NOT_YET_RECRUITING

Ghent, Oost-Vlaanderen, 9000, Belgium
Local Institution - 0116
NOT_YET_RECRUITING

Villejuif, Val-de-Marne, 94800, France
Local Institution - 0119
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109-0922, United States
Local Institution - 0123
NOT_YET_RECRUITING

Bergamo, 24127, Italy
Local Institution - 0124
NOT_YET_RECRUITING

Boston, Massachusetts, 02114, United States
Local Institution - 0129
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Local Institution - 0134
NOT_YET_RECRUITING

Madison, Wisconsin, 53792, United States
Local Institution - 0142
NOT_YET_RECRUITING

Buffalo, New York, 14263, United States
Local Institution - 0146
NOT_YET_RECRUITING

Dublin, D08 E9P6, Ireland
Local Institution - 0148
NOT_YET_RECRUITING

Brussels, Bruxelles-Capitale, Région de, 1200, Belgium
Local Institution - 0150
NOT_YET_RECRUITING

Hksar, 999077, Hong Kong
Local Institution - 0155
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100071, China
Local Institution - 0170
NOT_YET_RECRUITING

New York, New York, 10016, United States
Local Institution - 0174
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Local Institution - 0181
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Local Institution - 0182
NOT_YET_RECRUITING

Aurora, Colorado, 80045, United States
Local Institution - 0184
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510060, China
Local Institution - 0185
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Mater Misericordiae University Hospital (MMUH)
RECRUITING

Dublin, 7, Ireland
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
Oslo Universitetssykehus HF, Ullevål
RECRUITING

Oslo, 0450, Norway
Seoul National University Hospital
RECRUITING

Seoul, Seoul-teukbyeolsi [Seoul], 03080, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, Seoul-teukbyeolsi [Seoul], 03722, South Korea
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
RECRUITING

Shanghai, Shanghai Municipality, 200131, China
The First Affiliated Hospital of Henan Medical University
RECRUITING

Xinxiang, Henan, 453100, China
UZ Brussel
RECRUITING

Brussels, Bruxelles-Capitale, Région de, 1090, Belgium
Universitaetsklinikum Hamburg
RECRUITING

Hamburg, 20246, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.